Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 367
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
The New England journal of medicine.
Times cited: 1591